Fosamax and Osteonecrosis of the Jaw: Understanding the Link and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

For decades, public health communication has centered on general health and science information, providing broad guidance on wellness and disease prevention. This legacy framework effectively educated populations on common risks and screening practices, from cancer awareness to chronic disease management. Within this context, the transition from general health messaging to specific occupational exposure concerns requires a careful shift in focus. The domain of mass production introduces distinct environmental and material exposures that differ markedly from lifestyle-based health advice. As manufacturing processes scale, the potential for workers to encounter substances with latent health effects becomes a critical consideration. This pivot moves from population-level health promotion to the identification of specific hazards within industrial settings. The concern now narrows to understanding how prolonged contact with certain compounds in production environments may correlate with adverse outcomes, necessitating a more targeted inquiry into exposure pathways and risk characterization. This transition acknowledges that while general health information serves a foundational role, the realities of mass production demand precise attention to occupational factors that may influence long-term well-being.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health information, we now focus on a specific medication-related condition: osteonecrosis of the jaw (ONJ) associated with Fosamax (alendronate). Fosamax is a bisphosphonate approved for osteoporosis and Paget's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While effective in reducing fractures, its use has been linked to ONJ, a condition of exposed, non-healing jawbone. Understanding this risk is crucial for patients and healthcare providers, especially those with occupational or therapeutic exposure to bisphosphonates.

Fosamax and ONJ: Mechanism and Clinical Presentation

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves bone exposure in the oral cavity, often with pain, swelling, and infection. Diagnosis is typically based on clinical examination and history, including exposure to bisphosphonates. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research suggests that bisphosphonates, including alendronate, may alter jawbone-specific responses. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This indicates that the jawbone's unique biology may contribute to its vulnerability to bisphosphonate-induced damage.

Risk Factors and Duration of Exposure

Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Evidence of Causation and Epidemiological Studies

Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax use and ONJ onset, as well as the presence of other risk factors. A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). This suggests that while the risk is low, it increases with longer exposure, supporting a causal link between Fosamax use and ONJ in some patients. In summary, the evidence indicates that Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors. The prescribing information includes warnings about this risk, and patients should be informed about the potential for ONJ, especially before undergoing invasive dental procedures. The timeline for harm can range from days to months after starting the drug, and the risk diminishes after discontinuation. For affected patients, establishing causation requires consideration of the temporal relationship, duration of exposure, and other contributing factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by increasing bone mass and reducing fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. It has been reported in patients taking bisphosphonates, including Fosamax. The risk increases with longer duration of use and presence of other risk factors such as invasive dental procedures, cancer, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long does it take for Fosamax to cause ONJ?

The time to onset of symptoms can range from one day to several months after starting the drug. In clinical studies, most patients experienced relief after stopping the drug, but some had recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What does the research say about the risk of ONJ with Fosamax?

A cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use. Absolute risks were low (0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.